Category: Uncategorized

• Why Medical Device Clinical Trial Cost Varies So Much
• The US Baseline: What a First-in-Human Trial Costs Domestically
  • Regulatory and IRB timelines
  • Per-subject costs in North America
  • CRO and operational overhead
  • The timeline tax
• Latin America: Where the Cost Advantage Actually Lives
  • Regulatory speed in specific jurisdictions
  • Site activation and per-subject economics
  • The compounding value of 12 months vs. 24 months
• What Drives Cost Differences at the Program Level
  • Single-vendor vs. multi-vendor coordination
  • Packaged vs. bespoke scoping
• How bioaccess® Structures the Cost Comparison
• A Practical Cost Framework for Founders
• FAQs
• Make the Cost Comparison Before You Commit

If you're a MedTech or biopharma founder with a fixed budget earmarked for your first-in-human milestone, where you run the trial matters as much as how you design it. The same protocol can carry dramatically different price tags depending on geography — and the gap isn't just about per-patient rates. It's about regulatory timelines, site activation delays, and the compounding cost of time when you're burning runway.

This article breaks down the real cost drivers behind a first-in-human medical device trial in the United States versus Latin America, so you can make a more informed decision before issuing an RFP.

---

Why Medical Device Clinical Trial Cost Varies So Much

A first-in-human trial isn't a single line item. Total cost is the sum of several distinct cost centers, and each one behaves differently depending on where you run the study.

The main buckets are:

• Regulatory and ethics approval fees and timelines
• Site activation costs (qualification, contracting, training)
• Per-subject costs (screening, procedures, follow-up, stipends)
• CRO management fees (project management, monitoring, data management)
• Clinical study report and submission preparation
• Overhead from delays (extended site management, sponsor team time, investor timeline pressure)

That last item is the one founders most consistently underestimate. A six-month regulatory delay in the US doesn't just cost you six months of CRO fees. It costs you six months of burn rate, a potentially missed funding milestone, and the compounding risk of a competitor reaching clinical data first.

---

The US Baseline: What a First-in-Human Trial Costs Domestically

Running a first-in-human medical device study in the United States under an IDE means navigating FDA review, IRB approval, and site contracting at academic medical centers or specialized Phase I clinics. None of those steps move quickly.

Regulatory and IRB timelines

FDA IDE review alone takes 30 days for a non-significant risk determination and up to 180 days for a significant risk device. IRB review at a single institution typically adds another 30–90 days. Multi-site studies multiply that burden. In practice, US sponsors routinely spend 6–12 months in the pre-enrollment phase before a single patient is screened.

Per-subject costs in North America

Per-subject cost in a US first-in-human study depends on device complexity, procedure intensity, imaging and core lab requirements, the number and length of follow-up visits, and site overhead at academic medical centers. Subject-related costs scale with every enrolled patient and every screen failure, and they come before contract research organization (CRO) fees, site management, or data work.

CRO and operational overhead

Large US CROs typically scope FIH engagements across multiple internal teams: regulatory affairs, clinical operations, data management, and medical writing each operate as separate cost centers. Sponsors coordinate across those silos, which adds both cost and timeline risk. For a medical device study with meaningful complexity, that structure makes a full-service FIH engagement through a major US CRO one of the largest lines in the budget.

The timeline tax

At a typical seed-to-Series-B burn rate, 18–24 months of US trial execution represents a material portion of a funding round. If your Series A closes in Q3 and your board expects first human data before your Series B roadshow, a 24-month US timeline doesn't fit. That gap is where Latin America stops being operationally interesting and starts being financially necessary.

---

Latin America: Where the Cost Advantage Actually Lives

The cost advantage of running a first-in-human trial in Latin America is real — but it's more nuanced than a simple per-patient discount. The advantage compounds across three separate dimensions.

Regulatory speed in specific jurisdictions

Not all Latin American countries offer the same regulatory environment. In Panama, El Salvador, Chile, and the Dominican Republic, ethics and regulatory approvals are observed in 30–90 days. That's not a general claim about the region — it's specific to those four jurisdictions and the regulatory bodies that govern them: MINSA/CNBI in Panama, ISP/MINSAL in Chile, and SRS/CNEIS in El Salvador.

Compare that to 6–12 months in the US. For a founder on a 12–18 month runway, that difference can determine whether you hit a milestone or miss it.

Other Latin American markets — Argentina, Brazil, Colombia, Mexico, Peru — carry longer regulatory timelines that narrow or eliminate this advantage. Jurisdiction selection is not interchangeable.

Site activation and per-subject economics

Pre-qualified sites in Panama, El Salvador, Chile, and the Dominican Republic operate with lower overhead than US academic medical centers. Site activation timelines are shorter, contracting is more straightforward, and per-subject costs reflect a different economic baseline — producing meaningfully lower cost per enrolled subject compared to North American Phase I clinic rates.

This doesn't mean lower quality. Sites operating under ICH-GCP standards and ISO 14155 protocol architecture produce data that meets FDA requirements for foreign clinical data acceptance under 21 CFR 812.28. The cost savings don't come at the expense of regulatory usability.

The compounding value of 12 months vs. 24 months

If a US trial takes 18–24 months and a structured Latin America program delivers a submission-ready evidence package within 12 months, the cost comparison isn't just about per-patient rates. It's about total capital consumed during the trial period.

A 12-month program means:

• Fewer months of CRO management fees
• Less sponsor team time allocated to trial oversight
• A faster path to the data package that unlocks the next funding round
• Lower risk of timeline-driven dilution or bridge financing

For a startup with a fixed allocation for the FIH milestone, every extra month of program time draws on the same budget through management fees, sponsor team time, and site maintenance — before you account for per-subject cost differences.

---

What Drives Cost Differences at the Program Level

Beyond geography, the structure of your CRO engagement has a significant impact on total cost. Two variables matter most.

Single-vendor vs. multi-vendor coordination

When a sponsor coordinates across separate regulatory, clinical operations, data management, and medical writing vendors, every handoff creates cost and delay. Scope gaps between vendors generate change orders. Misaligned timelines create idle time that still gets billed.

A single-vendor engagement — where one accountable team manages all workstreams from protocol development through final clinical study report — eliminates most of that friction. The savings from reduced coordination overhead are real, even if they're harder to quantify on a line-item basis than per-subject rates.

Packaged vs. bespoke scoping

Large CROs typically scope FIH studies from scratch, which means weeks of back-and-forth on protocol, budget, and timeline before a contract is signed. A structured program with defined workstreams and a fixed timeline framework reduces pre-contract friction and gives sponsors a clearer picture of total program cost before they commit.

---

How bioaccess® Structures the Cost Comparison

bioaccess® operates specifically in Panama, El Salvador, Chile, and the Dominican Republic — the four jurisdictions where 30–90 day regulatory approvals are achievable. Its FIH-12™ program is a nine-workstream engagement that takes a sponsor from protocol development to a submission-ready evidence package within 12 months, managed by one accountable team.

That structure addresses both the geographic cost advantage and the coordination overhead problem at once. Sponsors don't manage separate regulatory, clinical, and data vendors. One team handles FDA strategy alignment, protocol development, site activation, patient enrollment, data management, and final clinical study report delivery — start to finish.

The program is built specifically for seed-to-Series-B startups whose capital cycles don't accommodate 18–24 month US timelines. All data is structured for FDA acceptance under 21 CFR 812.28, so the evidence package produced in Latin America is directly usable for US IDE and IND submissions.

Pricing is not publicly disclosed. bioaccess® offers a FIH Launch Planner — a six-question tool that generates a preliminary country route, timeline range, and evidence package estimate based on your device class. Intake is limited to 8 new programs per quarter.

---

A Practical Cost Framework for Founders

If you're building a budget for your FIH milestone, here's how the two paths compare:

US-based FIH trial (IDE pathway):

• Regulatory and IRB timeline: 6–12 months pre-enrollment
• Per-subject costs: driven by device complexity, procedure intensity, imaging, follow-up length, and academic site overhead
• CRO management: typically scoped across multiple internal teams
• Total program timeline: 18–24 months common for medical device FIH studies
• Data usability: directly FDA-applicable

Latin America FIH trial (bioaccess® FIH-12™, specific jurisdictions):

• Regulatory and ethics timeline: 30–90 days in Panama, El Salvador, Chile, Dominican Republic
• Per-subject costs: lower than North American baseline given site economics
• CRO management: single-vendor, nine-workstream accountability
• Total program timeline: 12 months under the FIH-12™ structured program
• Data usability: FDA-accepted under 21 CFR 812.28

The decision isn't purely about cost per subject. It's about total capital consumed, how well the timeline fits your funding cycle, and the risk profile of each path.

---

FAQs

Is data from a Latin American first-in-human trial accepted by the FDA?

Yes, when structured correctly. The FDA accepts foreign clinical data under 21 CFR 812.28, provided the study meets applicable standards. bioaccess® structures all FIH data under ICH-GCP and ISO 14155 protocol architecture specifically to meet this requirement, making the evidence package usable for US IDE and IND submissions.

Why are regulatory approvals faster in Panama, El Salvador, Chile, and the Dominican Republic than in the US?

These jurisdictions have streamlined ethics and regulatory review processes that operate on 30–90 day timelines. This is specific to these four countries and the regulatory bodies governing them — MINSA/CNBI in Panama, ISP/MINSAL in Chile, and SRS/CNEIS in El Salvador. It does not apply to Latin America broadly; markets like Brazil or Argentina carry longer timelines.

What drives per-subject cost in a first-in-human device trial?

Per-subject cost depends on device complexity, procedure intensity, imaging and core lab requirements, the number and length of follow-up visits, screen failure rates, and site overhead. Import and logistics for the investigational device and clinical trial insurance add to the study total. Ask any CRO to itemize these drivers so proposals can be compared line by line.

Does running a trial in Latin America mean lower data quality?

No. Sites operating under ICH-GCP standards and ISO 14155 protocol architecture meet the same quality standards required for FDA submission. The cost difference reflects site economics — not a reduction in data integrity or regulatory usability.

What is the FIH-12™ program and how does it affect total trial cost?

FIH-12™ is bioaccess®'s structured nine-workstream program that delivers a submission-ready evidence package within 12 months. Because one team manages all workstreams — from FDA strategy alignment through final clinical study report — sponsors avoid the coordination overhead and change order risk that comes with multi-vendor engagements. That structure affects total cost as much as per-subject rates do.

How does the 12-month timeline affect startup fundraising?

Most seed-to-Series-B MedTech founders need first human data before their next funding round closes. A 12-month program fits within a typical Series A-to-Series-B window. An 18–24 month US timeline often doesn't, which forces founders into bridge financing or timeline compression — both of which carry their own costs and risks.

How do I get a cost estimate for a Latin American FIH trial?

bioaccess® does not publish pricing publicly. The FIH Launch Planner on the website generates a preliminary country route, timeline range, and evidence package estimate based on six questions about your device class and program stage. Intake is limited to 8 new programs per quarter.

---

Make the Cost Comparison Before You Commit

The cost of a first-in-human trial isn't fixed by your protocol. It's shaped by where you run it, how your CRO is structured, and how well the program timeline fits your capital cycle.

If you're 12–24 months from needing first human data and your funding window doesn't accommodate a 24-month US timeline, the Latin America comparison is worth running in detail — not as a fallback, but as a primary strategic option.

Use the FIH Launch Planner at bioaccessla.com to get a preliminary country route and timeline estimate for your specific device class.

• Why FIH Budgets Are Hard to Estimate Early
• The Major Cost Drivers in a Medical Device FIH Study
  • 1. Regulatory Strategy and Pre-Submission Work
  • 2. Ethics and Regulatory Approval Timelines
  • 3. Site Activation and Investigator Fees
  • 4. Patient Enrollment
  • 5. Data Management and EDC
  • 6. Safety Monitoring and Adverse Event Reporting
  • 7. Clinical Study Report and Submission Package
• How Program Structure Affects Total Cost
• Geography as a Budget Variable
• Common Budget Mistakes to Avoid
• Building a Budget That Fits Your Capital Cycle
• FAQs

Planning a clinical trial budget is one of the most consequential decisions a medical device startup makes before first-in-human work begins. Get it right, and you protect your runway while hitting the data milestone your next funding round depends on. Get it wrong, and you either burn cash on delays or arrive at your Series B with incomplete evidence.

This article breaks down the real cost drivers in a first-in-human (FIH) medical device study — where budgets tend to slip, and how geography and program structure affect what you actually spend.

---

Why FIH Budgets Are Hard to Estimate Early

Most founders underestimate FIH costs because they anchor on a single line item — usually the CRO fee — and treat everything else as rounding error. In practice, that fee is only one component of a budget that spans regulatory strategy, site operations, patient enrollment, data management, and submission preparation.

The other common mistake is treating a US-based CRO quote as the only benchmark. US trial infrastructure carries a cost structure built for large pharma programs. When a startup with $2 million allocated for FIH work receives a quote sized for a 24-month, multi-site Phase I at a US academic medical center, the numbers rarely fit.

---

The Major Cost Drivers in a Medical Device FIH Study

1. Regulatory Strategy and Pre-Submission Work

Before a single patient is enrolled, you need a clear FDA pathway and a protocol that will generate data FDA will accept. That means Pre-Sub meetings, IDE preparation where applicable, and protocol architecture aligned to your 510(k), De Novo, PMA, or HDE route.

This workstream is consistently underbudgeted because it feels like planning rather than execution. But a protocol that misaligns with your intended regulatory pathway can force an amendment mid-study — and amendments cost both time and money. Solid regulatory strategy work at the front end is one of the most cost-efficient investments in the entire budget.

2. Ethics and Regulatory Approval Timelines

Approval timelines directly affect burn rate. Every month your study sits in a regulatory queue is a month of overhead, staff time, and deferred data.

In the US and EU, ethics and regulatory approvals typically take 6 to 12 months. In Panama, El Salvador, Chile, and the Dominican Republic, the same approvals are observed in 30 to 90 days. That difference alone can represent several hundred thousand dollars in carrying costs for a startup maintaining a standing team, device inventory, and site readiness while waiting.

Geography is a budget variable, not just a logistics preference.

3. Site Activation and Investigator Fees

Site activation covers site qualification, contract negotiation, ethics submissions at the site level, and investigator training. For a multi-site study, these costs multiply quickly.

Investigator fees vary significantly by country and specialty. Device trials requiring surgical implantation or specialized procedural skills command higher per-procedure fees than simpler interventional studies. Budgeting accurately here requires knowing your device category, the investigator profile the protocol demands, and the site's patient volume in your target indication.

Working with a network of pre-qualified sites reduces activation time and can lower the cost of feasibility work. A CRO with established site relationships doesn't need to rebuild that infrastructure from scratch for each new sponsor.

4. Patient Enrollment

Enrollment is where most FIH budgets experience their largest unplanned overruns. The primary causes are overly optimistic enrollment rate assumptions and underestimated screen failure rates.

Eligibility criteria in medical device FIH studies tend to be narrow. You may need a specific anatomical profile, disease severity range, or prior treatment history. Screen failure rates of 30 to 50 percent are common. If your budget assumes a one-to-one screening-to-enrollment ratio, you will run out of money before you hit your sample size.

Enrollment costs include patient stipends, screening visits, protocol-required diagnostics, and site staff time per patient contact. In jurisdictions with strong patient availability for your indication and experienced site coordinators, these costs are lower and enrollment moves faster.

5. Data Management and EDC

Electronic data capture setup, data entry, query resolution, and database lock are both fixed and variable costs that scale with protocol complexity and visit count. A lean protocol with fewer endpoints and fewer visits costs less to manage than a heavily instrumented study.

This is worth considering at the protocol design stage. Every additional data collection point adds cost downstream. Protocol authors who haven't managed data operations often add endpoints that sound useful but are expensive to collect and never appear in the final submission package.

6. Safety Monitoring and Adverse Event Reporting

For a first-in-human study, safety monitoring is non-negotiable. This includes a Data Safety Monitoring Board or equivalent independent review, Medical Monitor fees, and the infrastructure to capture, adjudicate, and report adverse events in compliance with ICH-GCP and ISO 14155 standards.

Adverse event reporting workflows that are well-structured from the outset cost less to operate than those assembled after enrollment begins.

7. Clinical Study Report and Submission Package

The end product of a FIH study is not raw data. It is a clinical study report and an organized data room structured for your next FDA regulatory step. Under FDA 21 CFR 812.28, foreign clinical data collected under the appropriate framework is accepted for US IDE and IND submissions — but the data must be organized and presented in a format FDA can use.

Sponsors who treat the CSR as an afterthought often face significant cost and time reconstructing documentation that should have been captured prospectively. Building the submission package into the program from day one keeps this cost predictable.

---

How Program Structure Affects Total Cost

The difference between a structured FIH program and a fragmented vendor approach is meaningful from a budget standpoint.

When a sponsor coordinates regulatory consultants, a CRO, a site management organization, a data management vendor, and a medical writer as separate contracts, they pay for the overhead of managing all those relationships. Each vendor has its own scope boundaries, change order process, and communication overhead. Gaps between vendor scopes become the sponsor's problem to resolve — and resolving them costs money.

A single-vendor program covering all workstreams under one engagement eliminates that coordination tax. It also makes the budget more predictable because scope is defined once, not renegotiated across five separate contracts.

bioaccess® structures its FIH-12™ program around nine workstreams managed by one accountable team — from FDA strategy alignment and protocol development through site activation, enrollment, data management, and final submission-ready evidence package delivery. The 12-month timeline is designed to fit within a startup's capital cycle between funding rounds.

---

Geography as a Budget Variable

Running a FIH study in the US is not inherently more rigorous than running one in a jurisdiction with faster approvals. What matters is whether the data is collected under a framework FDA will accept and whether the protocol architecture meets the applicable standard.

Under FDA 21 CFR 812.28, clinical data collected outside the US is accepted for US regulatory submissions when the study meets applicable requirements. Protocols built to ISO 14155 architecture, with ACRP-certified clinical operations, produce data that travels to FDA submissions.

The budget implication is direct. A 30 to 90-day approval window in Panama, El Salvador, Chile, or the Dominican Republic versus a 6 to 12-month window in the US means a faster enrollment start, lower carrying costs, and a submission-ready dataset delivered within a timeline that aligns with your next funding milestone.

---

Common Budget Mistakes to Avoid

Anchoring on a single line item. The CRO fee is visible; site costs, regulatory delays, and screen failure overruns are not. Budget for the full program, not just the contract.

Underestimating screen failures. Build a realistic screen failure assumption into your enrollment budget from the start. For most device FIH studies, plan for at least a 2:1 screening-to-enrollment ratio.

Treating submission preparation as separate. The CSR and data room are part of the study, not a separate project. If your budget doesn't include them, your total cost estimate is incomplete.

Ignoring approval timeline costs. A 9-month regulatory queue is not free. It carries a real cost in staff time, site readiness, and deferred data. Factor approval timelines into your total program cost, not just your CRO fee.

Choosing a CRO by lowest fee. A low CRO fee attached to a 24-month timeline and fragmented workstreams may cost more in total than a higher fee attached to a 12-month structured program with single-vendor accountability.

---

Building a Budget That Fits Your Capital Cycle

For seed-to-Series-B medical device startups, the FIH budget is not purely a clinical operations question — it is a capital strategy question. The goal is a submission-ready dataset before your next funding round closes, delivered within the $1 million to $5 million range most early-stage programs are working with.

That requires a program structure where timeline, scope, and cost are defined together, not independently. It requires a geography where approvals don't consume half your runway. And it requires a CRO that can deliver the full evidence package, not just enrollment.

The early-phase CRO services market reached USD 6.73 billion in 2026 per Mordor Intelligence, reflecting how central this decision has become for life sciences startups. Choosing the right program structure and jurisdiction is one of the highest-leverage decisions in that market.

If you are at the stage of building your FIH budget, the bioaccess® FIH Launch Planner generates a preliminary country route, timeline range, and evidence package estimate from six sponsor inputs — a practical starting point before you issue an RFP.

---

FAQs

What is a realistic budget range for a medical device FIH study?
Most medical device FIH studies at seed-to-Series-B startups fall in the $1 million to $5 million range, depending on device complexity, sample size, number of sites, and the jurisdiction where the study runs. This range covers regulatory strategy, site activation, enrollment, data management, and submission preparation.

Does running a FIH study in Latin America cost less than running one in the US?
Geography affects both direct costs and timeline costs. In Panama, El Salvador, Chile, and the Dominican Republic, regulatory approvals take 30 to 90 days versus 6 to 12 months in the US. Faster approvals reduce carrying costs and get you to enrollment sooner, which affects total program cost in a meaningful way.

Will FDA accept data from a FIH study conducted in Latin America?
Under FDA 21 CFR 812.28, clinical data collected outside the US is accepted for US IDE and IND submissions when the study meets applicable requirements. Protocols built to ISO 14155 architecture and conducted under ICH-GCP standards produce data that supports US regulatory submissions. FDA acceptance of foreign clinical data under this framework is not unconditional approval of the trial itself, but the pathway is well-established.

What causes FIH clinical trial budgets to overrun?
The most common causes are underestimated screen failure rates, regulatory approval delays that extend carrying costs, scope gaps between fragmented vendors, and treating submission preparation as a separate project rather than part of the study budget.

How does a single-vendor CRO program affect budget predictability?
When one team manages all workstreams under a single engagement, scope is defined once and change orders are less frequent. Fragmented vendor models require sponsors to manage scope boundaries across multiple contracts, which creates cost exposure that is difficult to budget in advance.

What is the minimum sample size for a medical device FIH study?
There is no universal minimum. Sample size depends on your regulatory pathway, the endpoints you need to support, and the statistical requirements of your protocol. IDE feasibility studies often enroll 10 to 30 subjects, while studies supporting a 510(k) or De Novo may require larger cohorts. Your protocol architecture and FDA pathway determine the number.

When should a startup start planning its FIH budget?
Ideally 12 to 24 months before you need first human data. That window allows time for regulatory strategy alignment, protocol development, site selection, and approval processes without compressing your timeline. Starting budget planning after IDE approval or a Series A close is common, but it leaves less margin for adjustment.

---

Planning your clinical trial budget well before you need it is not excessive caution — it is how startups protect their runway and arrive at their next funding milestone with the data they promised. The decisions you make on program structure, geography, and vendor accountability shape not just what you spend, but whether you spend it on time.

• What PMA Means
• Which Devices Require PMA
• The PMA Application: What It Actually Contains
• The Role of First-in-Human Data in a PMA Program
• Why Sponsors Running PMA-Track Devices Look Beyond the US for FIH Studies
• PMA vs. Other FDA Pathways: A Practical Comparison
• What Makes a PMA Clinical Program Succeed
• Planning Your PMA Timeline as a Startup
• FAQs

If you're developing a high-risk medical device and someone tells you it needs a PMA, that's not a minor regulatory detail. It means your path to US market clearance will require the most demanding clinical evidence package the FDA asks for. Understanding what PMA means, when it applies, and what it actually demands from a clinical program is foundational for any MedTech founder planning their development timeline and capital strategy.

What PMA Means

PMA stands for Premarket Approval. It's the FDA's regulatory mechanism for Class III medical devices — those that sustain or support human life, are implanted in the body, or present a potential unreasonable risk of illness or injury.

Unlike the 510(k) pathway, which clears a device based on substantial equivalence to a predicate, PMA requires the sponsor to independently demonstrate that the device is safe and effective. The FDA isn't comparing your device to something already on the market. It's evaluating the scientific evidence you generate entirely on its own merits.

That distinction has significant consequences for clinical planning. A 510(k) submission can sometimes rely on bench testing and limited clinical data. A PMA application typically requires a full pivotal clinical trial with statistically powered endpoints — often preceded by first-in-human feasibility data to support the pivotal design.

Which Devices Require PMA

Class III is the operative classification. Devices automatically placed in Class III include those that are life-sustaining, life-supporting, or implanted, and for which there's insufficient information to determine that general controls and performance standards would provide reasonable assurance of safety and effectiveness.

Common examples include:

• Implantable cardiac defibrillators
• Left ventricular assist devices
• Cochlear implants
• Certain neurostimulation systems
• High-risk ophthalmic implants
• Novel vascular grafts without a predicate

A device can also be required to go through PMA if it was originally classified as Class III at the time of the Medical Device Amendments of 1976, or if a De Novo classification request is denied and the device remains Class III.

If you're unsure of your device's classification, the FDA's product code database and a Pre-Submission (Pre-Sub) meeting are the right starting points. Misclassifying your device early creates downstream risk that compounds as your program advances.

The PMA Application: What It Actually Contains

A complete PMA submission is a substantial document. The FDA reviews it against a defined set of required elements, and any deficiency can trigger a Major Deficiency letter that resets the review clock.

The core components include:

Device description and manufacturing information. Full technical documentation covering design specifications, materials, manufacturing processes, and quality system compliance.

Non-clinical laboratory studies. Bench testing, biocompatibility data, electrical safety, software validation, and animal study results. These preclinical studies establish the safety foundation before any human exposure.

Clinical investigation data. This is the weight-bearing component of most PMA applications. The FDA expects data from well-controlled clinical studies demonstrating that the device performs as intended in the target patient population. The clinical data section must include the study protocol, IRB approvals, patient demographics, primary and secondary endpoint results, adverse event reporting, and a complete clinical study report.

Risk-benefit analysis. A structured analysis showing that the probable benefits of the device outweigh its probable risks for the intended use population.

Proposed labeling. Draft instructions for use, indications, contraindications, warnings, and precautions.

References. Published literature supporting the scientific rationale and clinical context.

The FDA has 180 days to review a PMA application once it's accepted as complete — though the actual timeline from submission to approval is typically longer when you account for deficiency responses and panel meetings.

The Role of First-in-Human Data in a PMA Program

Most PMA-track devices don't go straight from animal studies to a pivotal trial. The standard development arc includes an early feasibility or first-in-human (FIH) study that generates initial safety and performance data in a small patient cohort, followed by a pivotal trial designed with the statistical power to support the PMA application.

The FIH study serves several functions. It confirms the device can be safely used in humans at all. It surfaces any unexpected adverse events that need to be addressed before scaling enrollment. It generates preliminary effectiveness signals that inform pivotal endpoint selection. And it produces the clinical evidence needed to support an IDE application for the pivotal trial — or to refine an existing one.

For startups on a Series A or Series B timeline, the FIH study is often the most capital-efficient milestone to hit before the next funding round. Investors want to see human data. A FIH dataset is what moves a device from "promising preclinical results" to "de-risked asset with clinical proof of concept."

The challenge is that running a FIH study in the US takes time. Ethics and regulatory approvals typically require 6–12 months before the first patient is enrolled. For a founder with 18 months of runway and a board milestone tied to a pivotal trial start, that timeline is a serious constraint.

Why Sponsors Running PMA-Track Devices Look Beyond the US for FIH Studies

FDA regulations under 21 CFR 812.28 explicitly permit the use of foreign clinical data in IDE and PMA submissions, provided the data was collected under conditions comparable to FDA standards and the studies were conducted in accordance with Good Clinical Practice.

This isn't a workaround. It's a documented regulatory framework that allows PMA-track sponsors to generate FIH data in jurisdictions with faster approval timelines, then use that data to support their US regulatory submissions.

Latin America has become a recognized jurisdiction for this purpose. Panama, El Salvador, Chile, and the Dominican Republic have ethics and regulatory review processes that operate on 30–90-day timelines — compared to the 6–12 months typical in the US. That difference can compress a FIH program by six months or more, which is material when your next funding round has a defined close date.

bioaccess® manages FIH clinical trials specifically for MedTech and Biopharma startups across these four jurisdictions. Its FIH-12™ program is a structured 9-workstream engagement designed to take a sponsor from protocol development to a submission-ready clinical evidence package within 12 months. Every study is aligned to the sponsor's intended US regulatory pathway from day one — PMA, IDE, 510(k), De Novo, or HDE — so the final data package is built for the sponsor's next FDA step.

PMA vs. Other FDA Pathways: A Practical Comparison

Understanding where PMA sits relative to other pathways helps clarify when it applies and when an alternative might be available.

Pathway	Device Class	Clinical Evidence Required	Typical Timeline
510(k)	Class II (mostly)	Substantial equivalence to predicate; clinical data often limited	3–12 months
De Novo	Class II (novel)	Performance data; clinical data may be required	12–24 months
PMA	Class III	Independent clinical trial demonstrating safety and effectiveness	3–7+ years total program
HDE	Class III (rare disease)	Probable benefit; less rigorous than full PMA	Similar to PMA but with lower evidence threshold

The Humanitarian Device Exemption (HDE) is worth noting for sponsors developing devices for conditions affecting fewer than 8,000 patients per year in the US. The evidence threshold is lower than a full PMA, but the pathway is only available for qualifying rare disease indications.

If your device is Class III but has a predicate cleared before the 1976 amendments, a 510(k) may still be available. That's a nuanced determination that requires Pre-Sub engagement with the FDA.

What Makes a PMA Clinical Program Succeed

The FDA's standard for PMA approval is "reasonable assurance of safety and effectiveness." That phrase sounds straightforward, but translating it into a clinical program that actually meets the standard requires several things to be true at once.

Endpoint selection must be clinically meaningful and measurable. The FDA won't approve a device based on surrogate endpoints alone if direct clinical benefit endpoints are feasible. Choosing endpoints that are both scientifically valid and practically achievable in your patient population is one of the most consequential decisions in PMA program design.

The study population must reflect the intended use population. Enrollment criteria that are too narrow produce data the FDA may not accept as generalizable. Criteria that are too broad create heterogeneity that obscures the safety and effectiveness signal.

Adverse event reporting must be complete and transparent. PMA reviewers scrutinize adverse event data closely. Incomplete or inconsistently reported events are a common source of Major Deficiency letters.

The clinical study report must be organized for FDA review. A PMA application isn't just a collection of data — it's a structured argument that the evidence supports approval. The clinical study report and supporting data room need to be organized in a way that makes the FDA reviewer's job tractable.

For startups, this last point is frequently underestimated. A well-organized, submission-ready evidence package can meaningfully accelerate FDA review. A disorganized one adds months to the process.

Planning Your PMA Timeline as a Startup

A full PMA program from FIH study to approval typically spans several years. That doesn't mean every phase needs to move at the same pace. The FIH and early feasibility phases are where startups have the most flexibility to compress timelines, because the regulatory approval bottleneck is shorter and enrollment numbers are smaller.

A realistic planning framework for a PMA-track device looks something like this:

1. Pre-clinical completion and design freeze. Bench testing, biocompatibility, and animal studies complete. Design locked.
2. Pre-Sub meeting with FDA. Confirm classification, discuss IDE requirements, and align on the clinical evidence needed for PMA.
3. FIH / early feasibility study. Small cohort — typically 5–30 patients — to establish initial safety and performance data. This is where Latin American jurisdictions with 30–90-day approval timelines offer a meaningful speed advantage.
4. IDE application for pivotal trial. FIH data supports the IDE. FDA review takes approximately 30 days for non-significant risk determinations, or up to 30 days after receipt for significant risk devices.
5. Pivotal clinical trial. Statistically powered enrollment. This is the weight-bearing clinical phase for the PMA application.
6. PMA submission and review. 180-day statutory review period, plus time for deficiency responses.

Founders who treat the FIH study as a capital-efficient milestone — rather than a regulatory formality — tend to enter the pivotal phase with better data, a more refined protocol, and a stronger investor narrative.

---

FAQs

What does PMA stand for in medical devices?
PMA stands for Premarket Approval. It's the FDA's most rigorous review process for Class III medical devices, requiring the sponsor to independently demonstrate that the device is safe and effective through clinical evidence — not by showing equivalence to a predicate device.

What is the difference between a 510(k) and a PMA?
A 510(k) clears a device based on substantial equivalence to a legally marketed predicate. A PMA requires the sponsor to generate original clinical evidence demonstrating safety and effectiveness. PMA applies to Class III devices; 510(k) applies primarily to Class II. The evidentiary burden and timeline for PMA are substantially higher.

Does a PMA application require a clinical trial?
In most cases, yes. PMA applications for novel Class III devices typically require data from at least one well-controlled clinical investigation. For many devices, the program includes an early feasibility or first-in-human study followed by a pivotal trial with statistically powered enrollment.

Can foreign clinical data be used in a PMA submission?
Yes. Under FDA 21 CFR 812.28, foreign clinical data may support a PMA application if it was collected under conditions comparable to FDA standards and the study was conducted in accordance with Good Clinical Practice. This is a documented regulatory framework, not an exception.

How long does PMA approval take?
The FDA has a 180-day statutory review period once a PMA application is accepted as complete. The total time from initial FIH study to PMA approval — including all clinical phases — typically spans several years, depending on device complexity, enrollment timelines, and the number of deficiency cycles during review.

What is a Humanitarian Device Exemption (HDE) and how does it differ from PMA?
An HDE is a pathway for Class III devices intended to treat or diagnose conditions affecting fewer than 8,000 patients per year in the US. The evidentiary standard is "probable benefit" rather than the full "reasonable assurance of safety and effectiveness" required for PMA. HDE-approved devices may not be sold for profit unless certain conditions are met.

When should a MedTech startup engage a CRO for a PMA-track device?
Before the FIH study — ideally during or immediately after the Pre-Sub meeting with FDA. Early engagement ensures the FIH protocol is designed to generate data that directly supports the IDE application and, ultimately, the PMA submission. Engaging a CRO after the FIH study is complete often means the data package needs to be restructured, which adds time and cost.

---

The meaning of PMA is straightforward on its face: it's the FDA's highest-evidence approval pathway for devices with the most direct impact on patient safety. What it means for your development program is more specific. Your clinical evidence package needs to be built from the ground up, and every study you run — starting with the first human exposure — needs to be structured to support that submission.

If you're planning a PMA-track program and want to understand how your FIH study fits into the broader regulatory strategy, bioaccess® works exclusively with MedTech and Biopharma startups on first-in-human programs aligned to FDA pathways including PMA, IDE, and De Novo.

• What Is an Investigator's Brochure?
• What an Investigator's Brochure Must Contain
• Why the IB Matters More Than Most Sponsors Realize
  • It Is the Foundation for Ethics Committee Review
  • It Sets the Risk Framework for Your Protocol
  • It Protects Investigators and Sponsors
  • It Must Be Updated Throughout the Trial
• Common Mistakes FIH Sponsors Make With the IB
• The IB in the Context of a First-in-Human Program
• What a Strong IB Looks Like in Practice
• Regulatory Alignment Across Jurisdictions
• Frequently Asked Questions

If you are preparing for a first-in-human trial, the investigator's brochure will be one of the first documents your regulatory reviewers, ethics committees, and clinical sites ask for. Yet many early-stage sponsors treat it as an afterthought — something to pull together in the weeks before submission rather than a document built in parallel with protocol development.

That approach creates delays. This article explains what an investigator's brochure is, what it must contain, and why having a complete, current version ready before you engage a CRO or submit to a regulatory authority is not just good practice — it is a prerequisite for moving fast.

What Is an Investigator’s Brochure?

An investigator's brochure (IB) is a compiled document that summarizes all clinical and non-clinical data relevant to studying an investigational product in human subjects. It gives the principal investigator and site staff what they need to understand the rationale for the trial, the expected risks and benefits, and how to manage participants safely.

For drug and biologic trials, the IB is required under ICH E6(R2) GCP guidelines. For medical device trials, the analogous document is often the Investigational Device Exemption (IDE) application or the Investigational Plan — but the underlying need is the same. Investigators require a consolidated reference that explains the device, its preclinical performance data, and the scientific basis for proceeding to human use.

The IB is not a marketing document. It is a scientific summary written for clinicians and regulators.

What an Investigator’s Brochure Must Contain

ICH E6(R2) sets out the standard structure. A complete IB typically includes:

• Title page and table of contents — sponsor name, product name or code, version number, and date
• Confidentiality statement — restricting use to investigators and ethics committees
• Summary — a brief synopsis of the physical, chemical, pharmaceutical, and pharmacological properties, and their clinical implications
• Introduction — the product name, active ingredients, pharmacological class, and rationale for conducting research
• Physical, chemical, and pharmaceutical properties — relevant to safety and handling, particularly important for radiopharmaceuticals and implantable devices
• Non-clinical studies — pharmacology, toxicology, pharmacokinetics, and metabolism data from animal or in vitro studies, with a discussion of findings and their relevance to human use
• Effects in humans — any prior human data, including compassionate use or early feasibility results if available
• Summary of data and guidance for the investigator — a concise risk-benefit assessment and practical guidance on dosing, monitoring, and adverse event management
• References — cited literature supporting the above sections

For medical devices specifically, the non-clinical section should include bench testing results, biocompatibility data, and any animal study outcomes. The summary should address the device's intended use and the basis for the proposed first-in-human use parameters.

Why the IB Matters More Than Most Sponsors Realize

It Is the Foundation for Ethics Committee Review

Before any clinical site in Panama, Chile, El Salvador, or the Dominican Republic can enroll a patient, the local ethics committee and national regulatory authority must review and approve the study. That review is grounded in the IB. Reviewers use it to assess whether the preclinical safety package justifies exposing humans to the investigational product.

An incomplete or poorly organized IB does not just slow down approval — it can trigger requests for additional data that take months to generate. In jurisdictions where regulatory approvals can move in 30 to 90 days, a weak IB is often the single biggest bottleneck sponsors create for themselves.

It Sets the Risk Framework for Your Protocol

The IB and the clinical protocol are co-dependent documents. Stopping rules, dose escalation criteria, adverse event monitoring thresholds, and inclusion/exclusion criteria should all be traceable back to the risk signals identified in the IB.

If you write the protocol before the IB is complete, you are making safety assumptions without a documented evidentiary basis. Regulators will notice. Ethics committees will ask where those assumptions came from.

It Protects Investigators and Sponsors

When an adverse event occurs during a trial, the IB is the reference point for determining whether the event was anticipated. An event that matches a known risk documented in the IB is handled differently from one that was not disclosed. A thorough, honest IB protects investigators by giving them accurate expectations — and it protects sponsors by demonstrating that known risks were disclosed to the site before enrollment began.

It Must Be Updated Throughout the Trial

The IB is a living document. ICH E6(R2) requires that it be reviewed at least annually and updated whenever new information materially changes the risk-benefit picture. If new safety signals emerge from parallel studies while your trial is ongoing, the IB must reflect that, and sites and ethics committees must receive updated versions promptly.

Sponsors who treat the IB as a document written once and filed away will find themselves out of compliance when auditors review the trial master file.

Common Mistakes FIH Sponsors Make With the IB

Starting too late. The IB should be drafted in parallel with preclinical work, not after it concludes. If animal studies are still running, draft the structure now and populate it as data becomes available.

Omitting negative findings. Regulators and ethics committees are not looking for a document that presents only favorable data. Omitting unfavorable preclinical findings does not make them disappear — it raises questions about sponsor credibility and can result in clinical holds.

Using inconsistent terminology. The product name, dose units, and adverse event terminology in the IB should match the protocol exactly. Discrepancies between documents create confusion during review and can delay approval.

Failing to localize for the operating jurisdiction. If your trial is running in Latin America, the IB may need to be available in Spanish depending on the country and the ethics committee's requirements. Sponsors who assume an English-only document will suffice in every jurisdiction often discover this requirement at the worst possible moment.

Not assigning version control. Every IB update must carry a new version number and date. Without it, sites may be working from outdated information without realizing it.

The IB in the Context of a First-in-Human Program

For a startup running its first FIH trial, the IB is one of nine workstreams that need to come together before a patient can be enrolled. It sits upstream of protocol development, site selection, ethics committee submission, and regulatory authority review.

The bioaccess® FIH-12 program is structured around exactly this kind of interdependency. One accountable team manages all nine workstreams — from FDA strategy alignment and protocol development through site activation, patient enrollment, data management, and delivery of a submission-ready clinical evidence package — within a 12-month timeline. That structure only works when foundational documents like the IB are treated as program-critical deliverables, not administrative tasks.

Sponsors who arrive with a complete, current IB move faster through regulatory review in Panama, El Salvador, Chile, and the Dominican Republic, where approvals run 30 to 90 days under normal conditions. Sponsors who arrive without one add weeks or months to a timeline that was already tight.

What a Strong IB Looks Like in Practice

A well-constructed IB for a first-in-human medical device trial typically runs 30 to 80 pages, depending on the volume of preclinical data. It should be organized so that a principal investigator who has never seen the device can read the summary section and come away with a clear understanding of the product, its intended use, the key preclinical findings, and the anticipated risks — in under 20 minutes.

The non-clinical section should be honest about data gaps. If a particular toxicology study has not been completed, say so and explain why the available data is sufficient to justify proceeding. Regulators are accustomed to early-stage programs with incomplete datasets. What they are not accustomed to is sponsors who do not acknowledge what they do not yet know.

The guidance section at the end should be practical: what investigators should watch for, how to grade adverse events using a recognized scale, when to contact the sponsor, and when to stop dosing or use. This section is consistently underdeveloped in first-time sponsor IBs.

Regulatory Alignment Across Jurisdictions

Running a multi-country FIH trial means the IB must satisfy the requirements of each operating jurisdiction's regulatory authority. In Panama, that means MINSA and CNBI. In Chile, ISP and MINSAL. In El Salvador, SRS and CNEIS. Each authority may have specific formatting or language requirements, and the ethics committee at each site may request additional sections or clarifications.

Building a single IB that satisfies all applicable requirements from the start is far more efficient than drafting one version and adapting it reactively. Sponsors who have been through this process before know that the time invested in a rigorous initial IB pays back in faster approvals and fewer revision cycles.

---

Frequently Asked Questions

What is an investigator's brochure in clinical trials?
An investigator's brochure is a document compiled by the sponsor that summarizes all relevant clinical and non-clinical data about an investigational product. It gives investigators the information they need to understand the scientific rationale for the trial and to manage participant safety. It is required under ICH E6(R2) GCP guidelines for drug and biologic trials and serves an equivalent function in medical device studies.

When should a sponsor prepare the investigator's brochure?
The IB should be drafted in parallel with preclinical work, not after it concludes. Waiting until all studies are complete before starting the IB adds unnecessary time to your regulatory submission timeline. Draft the structure early and populate it as data becomes available.

Does the investigator's brochure need to be updated during the trial?
Yes. ICH E6(R2) requires that the IB be reviewed at least annually and updated whenever new information materially affects the risk-benefit assessment. Updated versions must be distributed to all active sites and ethics committees promptly.

Is an investigator's brochure required for medical device trials?
The IB as defined by ICH E6(R2) applies primarily to drug and biologic trials. For medical devices, the equivalent information is typically included in the IDE application or the Investigational Plan. That said, many medical device sponsors also prepare an IB-style document because ethics committees and international regulatory authorities often expect one.

What happens if the investigator's brochure is incomplete at the time of regulatory submission?
An incomplete IB can trigger requests for additional data from the regulatory authority or ethics committee, extending the review timeline. In jurisdictions where approvals can otherwise move quickly, a weak IB is frequently the primary cause of delays.

How long should an investigator's brochure be for a first-in-human trial?
For a first-in-human medical device or biologic trial, a well-constructed IB typically runs 30 to 80 pages depending on the volume of preclinical data available. The priority is completeness and clarity, not length. A concise, well-organized IB is more useful to investigators and reviewers than a lengthy one that buries the information that matters.

Does the investigator's brochure need to be translated for Latin American trials?
It depends on the country and the ethics committee's requirements. In some jurisdictions, an English-language IB is acceptable. In others, a Spanish translation is required. Sponsors should confirm language requirements for each operating jurisdiction before finalizing the document.

---

The investigator's brochure is not a formality. It is the scientific case for why your trial should proceed and the practical guide that keeps investigators and patients safe once it does. Get it right before you start — and keep it current throughout. If you are planning a first-in-human program and want to understand how the IB fits into the full regulatory and operational sequence, bioaccess® works with sponsors from the earliest stages of trial planning.